Aug 27 (Reuters) – The European Medicines Agency on Thursday disclosed a shortage of an injectable medicine used to treat schizophrenia in some member EU states due to issues at contract manufacturer
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)